Cargando…

Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema

To predict the need for additional local corticosteroids after receiving the 0.19 mg fluocinolone acetonide (FAc) implant in patients with macular edema secondary to non-infectious uveitis previously treated with local peribulbar corticosteroids. The number of corticosteroids required prior FAc, vis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kessler, Lucy Joanne, Łabuz, Grzegorz, Auffarth, Gerd U., Khoramnia, Ramin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028038/ https://www.ncbi.nlm.nih.gov/pubmed/35456522 http://dx.doi.org/10.3390/pharmaceutics14040688

Ejemplares similares

Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
por: Kessler, Lucy Joanne, et al.
Publicado: (2023)

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
por: Weber, Lea F., et al.
Publicado: (2019)

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
por: Hikal, Muaas, et al.
Publicado: (2021)

Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant – A Case Report
por: Meira, Jorge, et al.
Publicado: (2019)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2020)

Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema
por: Minnella, Angelo Maria, et al.
Publicado: (2021)

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome
por: Marques, João Heitor, et al.
Publicado: (2021)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy
por: Lima-Fontes, Mário, et al.
Publicado: (2022)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho, João, et al.
Publicado: (2019)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review
por: Ribeiro, Flávio, et al.
Publicado: (2021)

Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema
por: Coney, Joseph M
Publicado: (2019)

Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema
por: Byun, Matthew, et al.
Publicado: (2020)

Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN(®) (0.19 mg fluocinolone acetonide implant)
por: Augustin, Albert J, et al.
Publicado: (2019)

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020)

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management
por: Brumm, Matthew V, et al.
Publicado: (2007)

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema
por: Singh, P, et al.
Publicado: (2018)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies
por: Ansari, Abdus Samad, et al.
Publicado: (2021)

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
por: Moll-Udina, Aina, et al.
Publicado: (2023)

Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
por: Fung, Simon, et al.
Publicado: (2022)

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
por: McCluskey, Jessica D, et al.
Publicado: (2019)

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
por: Haritoglou, Christos, et al.
Publicado: (2013)

Intravitreal Diclofenac for Refractory Uveitic Cystoid Macular Edema
por: Ramezani, Alireza, et al.
Publicado: (2013)

Intravitreal therapeutic agents in noninfectious uveitic macular edema
por: Shah, Kunal Kaushik, et al.
Publicado: (2018)

Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve
por: Battista, Marco, et al.
Publicado: (2021)

Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
por: Fung, Simon, et al.
Publicado: (2022)

Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)—results from the ILUVIT study
por: Deuchler, Svenja K., et al.
Publicado: (2022)

Ellipsoid Zone Integrity and Visual Acuity Changes during Diabetic Macular Edema Therapy: A Longitudinal Study
por: Kessler, Lucy J., et al.
Publicado: (2021)

Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant
por: Siddiqui, Yousuf, et al.
Publicado: (2022)

The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema
por: Al-Dhibi, Hassan, et al.
Publicado: (2014)

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
por: Elbarky, Ahmed Mohammed
Publicado: (2020)

Two-Photon Vision in Age-Related Macular Degeneration: A Translational Study
por: Łabuz, Grzegorz, et al.
Publicado: (2022)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Diagnostic Techniques to Increase the Safety of Phakic Intraocular Lenses
por: Naujokaitis, Tadas, et al.
Publicado: (2023)

Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study
por: Buhl, Lara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_97bm3rk5641rp3t74qak0bkoin